Nuclear Magnetic Resonance Based Metabolomics and Liver Diseases: Recent Advances and Future Clinical Applications

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Jan 13

PMID 26755887

Citations 23

Authors

Roland Amathieu

Mohamed Nawfal Triba

Corentine Goossens

Nadia Bouchemal

Pierre Nahon

Philippe Savarin

Laurence Le Moyec

Affiliations

Soon will be listed here.

Abstract

Metabolomics is defined as the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification. It is an "omics" technique that is situated downstream of genomics, transcriptomics and proteomics. Metabolomics is recognized as a promising technique in the field of systems biology for the evaluation of global metabolic changes. During the last decade, metabolomics approaches have become widely used in the study of liver diseases for the detection of early biomarkers and altered metabolic pathways. It is a powerful technique to improve our pathophysiological knowledge of various liver diseases. It can be a useful tool to help clinicians in the diagnostic process especially to distinguish malignant and non-malignant liver disease as well as to determine the etiology or severity of the liver disease. It can also assess therapeutic response or predict drug induced liver injury. Nevertheless, the usefulness of metabolomics is often not understood by clinicians, especially the concept of metabolomics profiling or fingerprinting. In the present work, after a concise description of the different techniques and processes used in metabolomics, we will review the main research on this subject by focusing specifically on in vitro proton nuclear magnetic resonance spectroscopy based metabolomics approaches in human studies. We will first consider the clinical point of view enlighten physicians on this new approach and emphasis its future use in clinical "routine".

Citing Articles

Serum Metabolomics and NF-κB Pathway Analysis Revealed the Antipyretic Mechanism of Ellagic Acid on LPS-Induced Fever in Rabbits.

Xie F, Xu L, Zhu H, Yu X, Deng L, Qin H Metabolites. 2024; 14(8).

PMID: 39195502 PMC: 11356007. DOI: 10.3390/metabo14080407.

Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet.

Dai Y, Fan H, Huang K, Sun X, Zhao Z, Liu C World J Hepatol. 2023; 15(9):1043-1059.

PMID: 37900214 PMC: 10600694. DOI: 10.4254/wjh.v15.i9.1043.

Optical Biosensors for the Diagnosis of COVID-19 and Other Viruses-A Review.

John P, Vasa N, Zam A Diagnostics (Basel). 2023; 13(14).

PMID: 37510162 PMC: 10378272. DOI: 10.3390/diagnostics13142418.

Spatial metabolomics and its application in the liver.

Santos A, C Delgado T, Marques V, Ramirez-Moncayo C, Alonso C, Vidal-Puig A Hepatology. 2023; 79(5):1158-1179.

PMID: 36811413 PMC: 11020039. DOI: 10.1097/HEP.0000000000000341.

Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics.

Berkemeyer S Int J Mol Sci. 2023; 24(3).

PMID: 36768732 PMC: 9916415. DOI: 10.3390/ijms24032409.

References

Dunn W, Bailey N, Johnson H . Measuring the metabolome: current analytical technologies. Analyst. 2005; 130(5):606-25. DOI: 10.1039/b418288j. View

Andersson U, Lindberg J, Wang S, Balasubramanian R, Marcusson-Stahl M, Hannula M . A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers. 2009; 14(8):572-86. DOI: 10.3109/13547500903261354. View

Dunn W, Broadhurst D, Atherton H, Goodacre R, Griffin J . Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2010; 40(1):387-426. DOI: 10.1039/b906712b. View

Amathieu R, Triba M, Nahon P, Bouchemal N, Kamoun W, Haouache H . Serum 1H-NMR metabolomic fingerprints of acute-on-chronic liver failure in intensive care unit patients with alcoholic cirrhosis. PLoS One. 2014; 9(2):e89230. PMC: 3929651. DOI: 10.1371/journal.pone.0089230. View

Psychogios N, Hau D, Peng J, Guo A, Mandal R, Bouatra S . The human serum metabolome. PLoS One. 2011; 6(2):e16957. PMC: 3040193. DOI: 10.1371/journal.pone.0016957. View

Wishart D, Tzur D, Knox C, Eisner R, Guo A, Young N . HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007; 35(Database issue):D521-6. PMC: 1899095. DOI: 10.1093/nar/gkl923. View

Clayton T, Baker D, Lindon J, Everett J, Nicholson J . Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009; 106(34):14728-33. PMC: 2731842. DOI: 10.1073/pnas.0904489106. View

Shariff M, Gomaa A, Cox I, Patel M, Williams H, Crossey M . Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res. 2011; 10(4):1828-36. DOI: 10.1021/pr101096f. View

Holmes E, Wilson I, Nicholson J . Metabolic phenotyping in health and disease. Cell. 2008; 134(5):714-7. DOI: 10.1016/j.cell.2008.08.026. View

10.

Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H . Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009; 100(4):782-5. PMC: 11159264. DOI: 10.1111/j.1349-7006.2009.01086.x. View

11.

Yu K, Sheng G, Sheng J, Chen Y, Xu W, Liu X . A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res. 2007; 6(7):2413-9. DOI: 10.1021/pr060591d. View

12.

Serkova N, Zhang Y, Coatney J, Hunter L, Wachs M, Niemann C . Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation. 2007; 83(4):517-21. PMC: 2709529. DOI: 10.1097/01.tp.0000251649.01148.f8. View

13.

Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y . Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res. 2007; 6(7):2605-14. DOI: 10.1021/pr070063h. View

14.

Wang J, Pu S, Sun Y, Li Z, Niu M, Yan X . Metabolomic Profiling of Autoimmune Hepatitis: The Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy. J Proteome Res. 2014; 13(8):3792-3801. DOI: 10.1021/pr500462f. View

15.

Jimenez B, Montoliu C, MacIntyre D, Serra M, Wassel A, Jover M . Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. J Proteome Res. 2010; 9(10):5180-7. DOI: 10.1021/pr100486e. View

16.

Martinez-Granados B, Morales J, Rodrigo J, Del Olmo J, Serra M, Ferrandez A . Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies. Int J Mol Med. 2010; 27(1):111-7. DOI: 10.3892/ijmm.2010.563. View

17.

Fernie A, Trethewey R, Krotzky A, Willmitzer L . Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol. 2004; 5(9):763-9. DOI: 10.1038/nrm1451. View

18.

Wen H, Yoo S, Kang J, Kim H, Park J, Jeong S . A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 2009; 52(2):228-33. DOI: 10.1016/j.jhep.2009.11.002. View

19.

Cobbold J, Patel J, Goldin R, North B, Crossey M, Fitzpatrick J . Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. J Hepatol. 2009; 52(1):16-24. DOI: 10.1016/j.jhep.2009.10.006. View

20.

Winnike J, Li Z, Wright F, MacDonald J, OConnell T, Watkins P . Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther. 2010; 88(1):45-51. DOI: 10.1038/clpt.2009.240. View